Fremont, CA

Novo Nordisk's Fremont site is central for stem cell R&D, including the process development and manufacturing of stem cell-based products for use in preclinical and clinical development programs. The state-of-the-art good manufacturing practice (GMP) facility has been renovated to support Novo Nordisk's continuously growing pipeline of stem cell R&D initiatives. These teams leverage stem cell technology to find new treatments for patients with diabetes and heart failure and are exploring other related chronic illness needs. We mature processes and produce stem cell-based Master Cell Banks, Working Cell Banks and final products for use in clinical trials. A close collaboration with the University of California, San Francisco, is a key strategic partner to the Fremont location.